With Arena Pharmaceuticals (ARNA +0.00%) and Eisai still waiting for their obesity drug Belviq to complete DEA scheduling, it was their chief rival VIVUS (VVUS +0.00%) that made news today. All eyes were on VIVUS' decision to take out a loan that could amount to $110 million.
But why is this necessary at all? Does the company need more capital to enhance its marketing strategy for the obesity drug Qsymia, or is this a signal that VIVUS is currently in a difficult financial situation? Health-care analyst Max Macaluso sheds light on this news in the following video.
